Press release
Investigation announced for Long-Term Investors in shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)
An investigation on behalf of current long term investors in Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) shares.
Investors who are current long term investors in Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: EIGR stocks follows a lawsuit filed against Eiger BioPharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: EIGR stocks, concerns whether certain Eiger BioPharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that, the Defendants made false and/or misleading statements and/or failed to disclose that Defendants overstated Eiger's clinical and regulatory drug development expertise, that Defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the peginterferon lambda EUA,that there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic, that as a result, the FDA was unlikely to approve the submission of a peginterferon lambda EUA, that as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) here
News-ID: 2877905 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Eiger
Congenital Hyperinsulinism Market to Exhibit Moderate Growth Rate till 2032, Inv …
DelveInsight's "Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congenital Hyperinsulinism Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Congenital Hyperinsulinism market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size…
Investigation announced for Investors in shares of Eiger BioPharmaceuticals, Inc …
An investigation was announced over potential securities laws violations by Eiger BioPharmaceuticals, Inc. in connection with certain financial statements.
Investors who purchased shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Eiger BioPharmaceuticals, Inc. regarding its business, its prospects and its operations were…
Hutchinson-Gilford Progeria Treatment Market to See Booming Growth 2022-2028 | E …
The research study presented here is an excellent compilation of various types of analyses of important aspects of the Global Hutchinson-Gilford Progeria Treatment Market. A devilishly researched analysis and Porter's five forces analysis, provide a deep explanation of the strengths and weaknesses of the global Hutchinson-Gilford Progeria Treatment market and the other players operating within it. The authors of the report also provided qualitative and quantitative analysis of several microeconomic…
Ubenimex Market to Witness Huge Growth by 2027 Covid-19 Analysis | Eiger BioPhar …
Ubenimex market research report has great importance in running business profitably since it gathers all the required information for the key players about latest advancements, market demand analysis, sales analysis and business tactics. It further focuses on market categorization on the basis of type, end user and region. Granular level information is provided here about size of market, market share and competitive evaluation for the estimated years 2021-2027. The quantitative…
Hepatitis D Virus (HDV) Infection Market Strategists and effective growth for ke …
Hepatitis D Virus Infection is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma.
Hepatitis D Virus Infection requires hepatitis B virus (HBV) for its replication. HDV infection occurs as co-infection or as…
Congenital Hyperinsulinism Market Accelerating CAGR +4% by 2028 with Teva Pharma …
Congenital Hyperinsulinism Market is projected to thrive at a CAGR +4% by the timeline of 2021-28.
Congenital hyperinsulinism is a rare genetic condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent episodes of low blood sugar (hypoglycemia).
Congenital Hyperinsulinism be cured by diffusing CHI affects the entire pancreas. It can be inherited in a…
